Antimicrobial-Resistant Neisseria gonorrhoeae Infections in Men Using Doxycycline Postexposure Prophylaxis: A Substudy of the ANRS 174 DOXYVAC Trial
Clinical Infectious Diseases · 08.07.2026 · 82 (6) · 1065-1074
DOI: 10.1093/cid/ciaf591 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 10.11.2025. Verfasst von Béatrice Berçot und 20 weiteren Autor:innen. Beteiligte Einrichtung: University Paris Cité and University Sorbonne Paris Nord, Inserm, IAME, Assistance-Publique Hôpitaux de Paris, Laboratory of Bacteriology, Hospital S…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Doxycycline, Drug Resistance, Bacterial, Gonorrhea. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: ANRS, MIE, National Agency for Research on AIDS.
Abstract (Originalsprache)
Background
Prevention of bacterial sexually transmitted infections prevention by doxycycline postexposure prophylaxis (DoxyPEP) in men who have sex with men has raised concerns about antimicrobial resistance (AMR). We studied the impact of DoxyPEP on Neisseria gonorrhoeae (gonococcus [GC]) AMR in the ANRS 174 DOXYVAC trial.
Methods
Men who have sex with men and were on human immunodeficiency virus preexposure prophylaxis randomized to DoxyPEP (n = 362) or no–postexposure prophylaxis (PEP) (n = 183) arms were tested for GC at baseline and every 3 months thereafter, by culture and nucleic acid amplification test (NAAT). Minimum inhibitory concentrations (MICs) were determined with Etest (bioMérieux) and interpreted according to European Committee on Antimicrobial Susceptibility Testing guidelines. We performed whole-genome sequencing and/or polymerase chain reaction sequencing on GC isolates and NAAT-positive samples, using Fisher exact tests for comparisons.
Results
From January 2021 to February 2023, MICs were determined for 78 GC isolates, and 233 NAAT-only GC-positive samples were analyzed to identify the molecular determinants of resistance. All GC isolates were resistant to tetracycline with a significant increase in the rate of high-level tetracycline resistance mediated by the tetM gene in the DoxyPEP arm compared with the no-PEP arm (35.5 vs 12.5%, respectively; P = .043). The MICs of ceftriaxone, fluoroquinolones, and azithromycin were similarly distributed in the DoxyPEP and no-PEP arms. All GC isolates were susceptible to ceftriaxone and cefixime, but isolates with decreased susceptibility to cefixime linked to the mosaic penA34.007 allele were more frequent in the DoxyPEP arm than the no-PEP arm (32.3% vs 10.0%, respectively; P = .033).
Conclusions
DoxyPEP use was associated with a significant increase in high-level tetracycline resistance and decreased susceptibility to cefixime in GC. AMR should therefore be closely monitored when using this strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Paris Cité and University Sorbonne Paris Nord, Inserm, IAME, Assistance-Publique Hôpitaux de Paris, Laboratory of Bacteriology, Hospital Saint-Louis and Lariboisière, Paris, France.
- Associated Laboratory of the French National Center for Bacterial Sexually Transmitted Infections, Saint Louis Hospital, Paris, France.
- Institut Pierre Louis D'Épidémiologie et de Santé Publique, Sorbonne Université, Inserm, Paris, France.
- University Paris Cité and University Sorbonne Paris Nord, Inserm, IAME, Department of Infectious Diseases, Hospital Saint-Louis and Lariboisière, Assistance-Publique Hôpitaux de Paris, Paris, France.
- University Paris Cité, Inserm U1342, Department of Infectious Diseases, Hospital Saint-Louis and Lariboisière, Assistance-Publique Hôpitaux de Paris, Paris, France.
- Department of Infectious Diseases, Hospital Tenon, Assistance-Publique Hôpitaux de Paris, Paris, France.
ORCID-Profile: Béatrice Berçot, François Caméléna, Geoffroy Liegeon, Mary Mainardis, Aymeric Braille, Laurence Slama, Cécile Bébéar, Jade Ghosn, Dominique Costagliola
Förderung
- ANRS
- MIE
- National Agency for Research on AIDS
- Emerging Infectious Diseases
Zitieren
APA
Berçot, B., Assoumou, L., Caméléna, F., Voitichouk, C., Mérimèche, M., Ouattara, M., Liegeon, G., Kaba, A. D., Manda, V., Mainardis, M., Braille, A., Pialoux, G., Katlama, C., Surgers, L., Slama, L., Bébéar, C., Ollivier, M., Ghosn, J., Costagliola, D., …, & ANRS 174 DOXYVAC Study Group (2026). Antimicrobial-Resistant Neisseria gonorrhoeae Infections in Men Using Doxycycline Postexposure Prophylaxis: A Substudy of the ANRS 174 DOXYVAC Trial. Clinical Infectious Diseases, 82(6), 1065-1074. https://doi.org/10.1093/cid/ciaf591
Vancouver
Berçot B, Assoumou L, Caméléna F, Voitichouk C, Mérimèche M, Ouattara M, et al. Antimicrobial-Resistant Neisseria gonorrhoeae Infections in Men Using Doxycycline Postexposure Prophylaxis: A Substudy of the ANRS 174 DOXYVAC Trial. Clinical Infectious Diseases. 2026;82(6):1065-1074. doi:10.1093/cid/ciaf591
BibTeX
@article{Berot2026,
author = {Berçot, Béatrice and Assoumou, Lambert and Caméléna, François and Voitichouk, Chloé and Mérimèche, Manel and Ouattara, Moussa and Liegeon, Geoffroy and Kaba, Aissata Didine and Manda, Victoria and Mainardis, Mary and Braille, Aymeric and Pialoux, Gilles and Katlama, Christine and Surgers, Laure and Slama, Laurence and Bébéar, Cécile and Ollivier, Manon and Ghosn, Jade and Costagliola, Dominique and Molina, Jean-Michel and ANRS 174 DOXYVAC Study Group, ANRS 174 DOXYVAC Study Group},
title = {Antimicrobial-Resistant Neisseria gonorrhoeae Infections in Men Using Doxycycline Postexposure Prophylaxis: A Substudy of the ANRS 174 DOXYVAC Trial},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {82},
number = {6},
pages = {1065--1074},
doi = {10.1093/cid/ciaf591}
}
EUVIMED